Drug Trial Radar · NCT03463044
Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects
Last checked: Nov 19, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Apr 1, 2016
Primary completion
Aug 25, 2016
Study completion Aug 25, 2016
Sponsor
- Lead sponsor
- InotremIndustry
- Sponsor type
- Industry
- Collaborators
- Richmond Pharmacology Limited
- First posted
- Mar 13, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This was a single center, randomized, placebo-controlled study with a sequential i.v. dose escalation cohorts design, to assess safety, tolerability and pharmacokinetics of MOTREM (nangibotide) in healthy volunteers
Conditions
- Healthy Subjects
Interventions
nangibotideDrug
Continous i.v. infusion
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability: the Number of Subjects Experiencing Treatment Emergent Adverse EventsTime frame: 30-44 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Richmond Pharmacology Ltd.
Croydon, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.